[Phase II study of FF-705 by Clinical Cooperative Study Group].

Abstract

Clinical efficacy of new fluorouridine derivative, FF-705, was studied in 108 patients with advanced malignant tumors. Partial responses were observed in 8 of 61 evaluable cases (13.1%): 4 of 9 patients with breast cancer, 1 of 19 patients with gastric cancer, 1 of 15 patients with lung cancer, 1 of 3 patients with kidney cancer and 1 of 1 patient with pancreas cancer. In the analysis of adverse effects of FF-705, gastrointestinal toxicity was major toxicity. Especially, diarrhea was observed in 41 of 108 patients (38.0%) within a total dose of 10 g shortly after drug administration.

• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 11 Issue 1 Pg. 150-6 (Jan 1984) ISSN: 0385-0684 [Print] Japan
• PMID: 6230055 (Publication Type: English Abstract, Journal Article)

Chemical References

• Capsules
• Floxuridine
• 2'-deoxy-3',5'-di-O-acetyl-5-fluoro-3-(3-methylbenzoyl)uridine

Topics

• Administration, Oral
• Adult
• Aged
• Breast Neoplasms (drug therapy)
• Capsules
• Colonic Neoplasms (drug therapy)
• Drug Administration Schedule
• Drug Evaluation
• Female
• Floxuridine (analogs & derivatives, therapeutic use)
• Humans
• Lung Neoplasms (drug therapy)
• Male
• Middle Aged
• Neoplasms (drug therapy)
• Stomach Neoplasms (drug therapy)